Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Sjoerd T T SchettersErnesto RodriguezLaura J W KruijssenMatheus H W CrommentuijnLouis BoonJan Van den BosscheJoke M M Den HaanYvette van KooykPublished in: Journal for immunotherapy of cancer (2021)
The combined analysis of myeloid and lymphoid populations in the TME during successful and non-successful PD1 ICB led to the discovery of monocyte-to-DC differentiation linked to expanding T-cell populations. This differentiation was found in patients during ICB, which was significantly higher during successful ICB. The finding of tumor-infiltrating monocytes and differentiating moDCs as druggable target for rational combination therapy opens new avenues of anti-tumor therapy design.
Keyphrases
- combination therapy
- dendritic cells
- end stage renal disease
- peripheral blood
- ejection fraction
- newly diagnosed
- endothelial cells
- small molecule
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- immune response
- stem cells
- oxidative stress
- acute myeloid leukemia
- bone marrow
- mesenchymal stem cells
- computed tomography
- patient reported outcomes
- genetic diversity
- single cell
- smoking cessation